A recent highly potent and specific ATP-binding site small molecule DYRK1A inhibitor has been reported that crosses the blood brain barrier with 1 and 100 μM PST-001 significantly reducing DYRK1A activity reversing cognitive deficits of mouse DS models (Stensen et al., 2021a). This evidence concerns the gene DYRK1A and Dravet syndrome.